Is Gilead Sciences (GILD) Cheap with Trodelvy and Yeztugo in Focus?

According to Simply Wall St analysis, Gilead Sciences (GILD) stock has delivered a strong 5-year run with returns of about 140%, yet current valuation checks paint a mixed picture. The overall score sits between clearly cheap and clearly expensive, while recent oncology and HIV news keeps expectations elevated.

Rating Change

No specific rating change was mentioned, but the analysis suggests that today's valuation needs to be backed by durable cash flows rather than just sentiment.

Analyst Rationale

The analyst notes that the strong past returns put pressure on current valuation to be supported by fundamentals. Regulatory approvals and positive momentum for Trodelvy and Yeztugo could boost future cash flows.

Context

The stock's long-term performance has been excellent, but valuation is not clear-cut. Other analysts may have different views, but the focus on new oncology drugs remains key.

What We Conclude

Investors should monitor Gilead's ability to convert positive momentum from its new drugs into sustainable cash flows to justify the current valuation.